Investment management company Carillon Tower Advisers released its “Carillon Eagle Small Cap Growth Fund” in the first quarter of 2025. A copy of the letter can be downloaded here. Small-cap stocks fell sharply in the first quarter, with the Russell 2000 Growth Index (down 11.12%) lagging behind the Russell 2000 Value Index (down 7.74%). In the Russell 2000 Growth Index, real estate grew 1.76%, which outperformed all sectors both absolutely and relatively. The only other sector that provides positive returns is consumer staple food, which rose 0.67%. Also, check the fund’s top five holdings to see its best options for 2025.

The Carillon Eagle Small Cap Growth Fund highlights such as the protagonist Therapeutics, Inc in its first-quarter 2025 investor letter. Stocks like (NASDAQ: PTGX). Therapeutics, Inc. (NASDAQ: PTGX) is a biopharmaceutical company. Therapeutics, Inc. (NASDAQ:PTGX) has a one-month return of 2.86%, and its shares account for 50.15% of its value over the past 52 weeks. May 23, 2025, the protagonist Therapeutics, Inc. (NASDAQ: PTGX) stock closed at $45.66 and had a market capitalization of $2.83 billion.

The Carillon Eagle Small Cap Growth Fund points out about the protagonist Therapeutics, Inc in its Q1 2025 Investor Lettle. (NASDAQ: PTGX) The following content:

“Therapeutics, Inc. (NASDAQ: PTGX) is a leading biotech company dedicated to developing drugs for rare and preventable diseases. The company has two key assets: Rusfertide for the treatment of excess cell therapy (a type of blood cancer) and Icotrokinra's Rusfertide for the treatment of psoriasis and ulcerative colitis. In the first quarter, a large pharmaceutical company announced that Icotrokinra reached its primary endpoint in a phase 2 trial in patients with ulcerative colitis, one of the highest clinical response rates for oral therapies to address the disease. This positive result leads to excellent performance of the stock. ”

A research scientist wearing a lab coat works precisely in a biopharmaceutical lab.

Therapeutics, Inc. (NASDAQ: PTGX) is not among the 30 most popular stocks in hedge funds. According to our database, 40 hedge fund portfolios hold the lead role Therapeutics, Inc at the end of the first quarter. (NASDAQ: PTGX), last quarter was 37. Although we acknowledge the protagonist Therapeutics, Inc. The potential of (NASDAQ:PTGX) is an investment, but our belief is that AI stocks have greater hope to offer higher returns and do so in a shorter time frame. If you are looking for AI stocks that are as promising as NVIDIA, but whose earnings are trading at less than 5 times the price, check out our report on undervalued AI stocks.